Full Breadth and Depth of Accuray’s Advanced, Personalized Radiation Treatment Capabilities Showcased at Estro 31

Sunnyvale, California (ots/PRNewswire) –

Conference Presentations Highlighted Benefits of the
CyberKnife(R) System’s

Motion Management and the TomoTherapy(R) System’s Daily

Accuray Incorporated , the premier radiation oncology company,
announced today that for the first time in Europe, at ESTRO 31
[http://www.estro-events.org/Pages/ESTRO31.aspx ], the Annual
Congress of the European Society for Therapeutic Radiology and
Oncology in Barcelona, Spain, the company showcased side-by-side the
CyberKnife(R) Robotic Radiosurgery System
[http://www.accuray.com/products/cyberknife-vsi-system ] and the
TomoTherapy(R) System [http://accuray.com/products/tomotherapy-system
] with a record 3,000 booth attendees. Additionally, during ESTRO
Accuray announced and displayed the availability of the VoLO(TM)
Planning Solution for the TomoTherapy System, a combination of a new
dose calculation algorithm (NVBB – Non-Voxel Broad Beam) and a
specifically designed computing hardware based on Graphics Processor
Unit (GPU) technology. The VoLO Planning Solution provides intuitive,
interactive plan generation, reducing significantly treatment
planning time while further enhancing treatment quality.

On Friday, May 11 Accuray hosted a symposium chaired by Prof,
Eric Lartigau, M.D., Ph.D., Oscar Lambret Cancer Center, Lille,
France. Euan S. Thomson, Ph.D., president and CEO of Accuray
presented the „Vision of Accuray“ and discussed Accuray’s continued
commitment to clinical and technical research and development.
Clinical data was presented by Dr. Noelle van der Voort van Zyp,
Erasmus MC – Daniel den Hoed Cancer Centre in Rotterdam, Netherlands
that demonstrated the benefits of CyberKnife SBRT (Stereotactic Body
Radiation Therapy) in the treatment of peripheral and centrally
located non-small cell lung cancer, including excellent local tumor
control and low toxicity. Prof. Vincent Gregoire, M.D., Ph.D., FRCR,
UCL-Saint Luc University Hospital, Brussels, Belgium, a TomoTherapy
site, discussed the potential need for adaptive treatment of head and
neck cancer, illustrating how daily image guidance could identify
modification in dose delivery compared to the planned dose
distribution, and could trigger plan adaptation based on changing
characteristics of tumor and organs at risk. Finally, Dr. Nicholas
van As, Royal Marsden, London, United Kingdom gave an overview of the
newly launched PACE study [http://www.accuray.com/media/press-release
and-imrt-treatmen ] , a multicenter randomized comparative clinical
study of CyberKnife prostate SBRT, surgery and conventionally
fractionated radiotherapy. With more than 300 people in attendance,
the symposium proved to be a successful meeting and a chance for
leaders in the field to share and present important clinical

„The combination of quality presentations on treatment outcomes
from both the CyberKnife and TomoTherapy Systems and the consistent
interest in Accuray’s new product offerings reinforces our place as
an innovative leader in the radiation oncology industry,“ said Euan
S. Thomson, Ph.D., president and chief executive officer of Accuray.
„Accuray has solidified its presence in advancing the standards for
SBRT and IG-IMRT treatment and continues to make strides toward
helping patients live longer, better lives.“

Continuing the expansion of clinical evidence for both the
CyberKnife and TomoTherapy Systems, more than 110 presentations on
experience with both technologies were presented as part of ESTRO’s
scientific program. In particular, Dr. Mischa Hoogeman, Erasmus
MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
presented seven years of clinical experience in real-time lung tumor
tracking using the CyberKnife System’s unique motion management
capabilities including the Synchrony(R) Respiratory Tracking System,
which enables real-time tracking and correction for tumors that move
with respiration. Dr. Hoogeman also reported outstanding technical
and clinical accuracy during treatment with the CyberKnife System
thus allowing for reduced margins and the ability to account for
uncertainty in target position. To date Erasmus has treated more than
700 tumors in the lung with the CyberKnife System. Additionally,
several abstracts focused on the systematic use of the TomoTherapy
System’s daily megavoltage computed tomography (MVCT) to ensure
accurate patient set-up and to permit accurate calculation of
delivered dose and sophisticated treatment plan adaptation. Dr. Nadia
Di Muzio, Istituto Scientifico H.S. Raffaele, Milano, Italy presented
the general rationale for adaptive radiotherapy including the group’s
work on adapting margins during IMRT for pre-op rectal cancer

Both the TomoTherapy and CyberKnife Systems allow for the
treatment of a broad range of applications throughout the body, as
demonstrated by reports of excellent clinical outcomes for a variety
of indications. These outcomes prove that both technologies allow
clinicians the opportunity to offer patients accurate and high
quality individualized treatments that best suit their individual

About Accuray

Accuray Incorporated , based in Sunnyvale, Calif., is the premier
radiation oncology company that develops, manufactures and sells
personalized innovative treatment solutions that set the standard of
care, with the aim of helping patients live longer, better lives. The
Company’s leading edge technologies – the CyberKnife and TomoTherapy
Systems – are designed to deliver radiosurgery, stereotactic body
radiation therapy, intensity modulated radiation therapy, image
guided radiation therapy, and adaptive radiation therapy. To date,
635 systems have been installed in leading hospitals around the
world. For more information, please visit http://www.accuray.com.

Safe Harbor Statement

Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to the
„safe harbor“ provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this press release relate,
but are not limited, to the anticipated benefits of the VoLO
technology, the Company’s ability to continue to enhance the
performance of its products, clinical efficiency and effectiveness
the products, and the Company’s leadership position in radiation
oncology innovation. Forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially from expectations, including risks detailed from time to
time under the heading „Risk Factors“ in the Company’s reports Form
10-Q for the first, second and third quarters of fiscal 2012.
Forward-looking statements speak only as of the date the statements
are made and are based on information available to the Company at the
time those statements are made and/or management’s good faith belief
as of that time with respect to future events. The Company assumes no
obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other
factors affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly, investors should
not place undue reliance on any forward-looking statements.

Rebecca Phillips
Public Relations Manager, Accuray
Sophie Baumont

ots Originaltext: Accuray
Im Internet recherchierbar: http://www.presseportal.de

Quelle: http://www.presseportal.de/pm/105397/2254490/full-breadth-and-depth-of-accuray-s-advanced-personalized-radiation-treatment-capabilities/api